Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

GHRP-6 vs Sermorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

GHRP-6

Anecdotal + Animal Studies

Sermorelin

Discontinued (FDA approval 1990; US withdrawal 2008)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

GHRP-6 Sermorelin
Class GHRP; ghrelin receptor agonist GHRH analog
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist with strong orexigenic effect Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release
Route SC / Intranasal SC injection
Half-life ~15-30 min ~10-20 min
Dosage (research) 100-300 mcg SC 2-3x daily 200-500 mcg SC at bedtime daily
Evidence tier Anecdotal + Animal Studies Discontinued (FDA approval 1990; US withdrawal 2008)
Research depth 163 indexed (PubMed 141 · CT 0 · EPMC 22) 149 indexed (PubMed 122 · CT 17 · EPMC 10)
Availability Research Chemical Compounding Restricted
Reported risks Strong hunger; cortisol/prolactin rise; water retention Injection site reactions; headache; flushing

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick GHRP-6 or Sermorelin?

Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between GHRP-6 and Sermorelin?

GHRP-6 is classed as GHRP; ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: GHRP-6, GHS-R1a agonist with strong orexigenic effect; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: GHRP-6, ~15-30 min; Sermorelin, ~10-20 min. Routes in published studies: GHRP-6, SC / Intranasal; Sermorelin, SC injection.

Which has stronger evidence, GHRP-6 or Sermorelin?

GHRP-6 and Sermorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.

Which is more accessible, GHRP-6 or Sermorelin?

Neither GHRP-6 nor Sermorelin is an FDA-approved drug. Catalog status: GHRP-6, Research Chemical; Sermorelin, Compounding Restricted. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are GHRP-6 and Sermorelin ever combined?

GHRP-6 and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…